141 related articles for article (PubMed ID: 23438379)
1. Immunology of melanoma.
Mukherji B
Clin Dermatol; 2013; 31(2):156-65. PubMed ID: 23438379
[TBL] [Abstract][Full Text] [Related]
2. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
3. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
4. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
5. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
7. Melanoma immunology: past, present and future.
Parmiani G; Castelli C; Santinami M; Rivoltini L
Curr Opin Oncol; 2007 Mar; 19(2):121-7. PubMed ID: 17272984
[TBL] [Abstract][Full Text] [Related]
8. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
Gajewski TF
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5256-61. PubMed ID: 17875753
[TBL] [Abstract][Full Text] [Related]
9. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
Engelhard VH; Bullock TN; Colella TA; Mullins DW
Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
[TBL] [Abstract][Full Text] [Related]
10. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
[TBL] [Abstract][Full Text] [Related]
11. Melanoma cancer vaccines and anti-tumor T cell responses.
Vujanovic L; Butterfield LH
J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
[TBL] [Abstract][Full Text] [Related]
12. Immunology and immunotherapy of human malignant melanoma.
Bystryn JC
Dermatol Clin; 1985 Apr; 3(2):327-34. PubMed ID: 2937585
[TBL] [Abstract][Full Text] [Related]
13. T-cell recognition of melanoma-associated antigens.
Castelli C; Rivoltini L; Andreola G; Carrabba M; Renkvist N; Parmiani G
J Cell Physiol; 2000 Mar; 182(3):323-31. PubMed ID: 10653598
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of advanced or metastatic melanoma.
Cebon J; Gedye C; John T; Davis ID
Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
[TBL] [Abstract][Full Text] [Related]
15. Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice.
Paschen A; Song M; Osen W; Nguyen XD; Mueller-Berghaus J; Fink D; Daniel N; Donzeau M; Nagel W; Kropshofer H; Schadendorf D
Clin Cancer Res; 2005 Jul; 11(14):5241-7. PubMed ID: 16033842
[TBL] [Abstract][Full Text] [Related]
16. Vaccines against advanced melanoma.
Blanchard T; Srivastava PK; Duan F
Clin Dermatol; 2013; 31(2):179-90. PubMed ID: 23438381
[TBL] [Abstract][Full Text] [Related]
17. [Immunotherapy of malignant melanoma--basic principles and novel therapeutic approaches].
Enk AH; Becker JC; Schuler G
J Dtsch Dermatol Ges; 2006 Aug; 4(8):635-45. PubMed ID: 16895565
[TBL] [Abstract][Full Text] [Related]
18. Active-specific immunization against melanoma: is the problem at the receiving end?
Monsurrò V; Wang E; Panelli MC; Nagorsen D; Jin P; Katia Z; Smith K; Ngalame Y; Even J; Marincola FM
Semin Cancer Biol; 2003 Dec; 13(6):473-80. PubMed ID: 15001166
[TBL] [Abstract][Full Text] [Related]
19. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
20. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
Berinstein NL
Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
